Argenx Buys Unnatural Products for $550 Million Upfront
Argenx will pay $550 million upfront for Unnatural Products, with total potential value of about $1.15 billion. Here are the deal terms and timing.

Argenx (ARGX) has agreed to acquire Unnatural Products, a private biotechnology company, in a deal valued at up to $1.15 billion, according to RTTNews. Argenx will pay $550 million upfront, and the rest of the value depends on future development and regulatory milestones.
The deal is expected to close by the end of 2026. Unnatural Products will keep operating from its Santa Cruz, California site as part of argenx’s global research organization.
The deal by the numbers
- $1.15 billion: the approximate total potential value of the transaction, including milestone-based payments.
- $550 million: the amount argenx will pay upfront.
- Contingent value rights (CVRs): the instrument that carries the additional payments. A CVR pays out only if set targets, here future development and regulatory milestones, are met.
- 2016: the year Unnatural Products was founded.
- More than two years: how long the two companies have already worked together on research, which the acquisition builds on.
- End of 2026: the expected closing date, subject to customary closing conditions.
What Unnatural Products does
The company is developing orally delivered macrocyclic peptide medicines. These therapies are meant to combine the precision of biologic drugs with the convenience of a pill, and are aimed at disease targets that have been hard to treat with conventional medicines.
Its platform combines AI-guided drug design, large-scale compound synthesis and biological screening to produce therapeutic candidates. Unnatural Products has partnerships with several pharmaceutical companies, including Novartis, Merck and BridgeBio.
What it means for argenx
Argenx said the acquisition adds a macrocyclic peptide discovery platform to its existing antibody engineering capabilities. The company said this could support the development of both oral and long-acting medicines. It described the purchase as a way to strengthen its drug discovery engine and broaden its technology base while it expands an immunology-focused pipeline.
For Unnatural Products staff, the announcement says the Santa Cruz site will continue to operate after closing. No job figures were disclosed. Existing partners such as Novartis, Merck and BridgeBio are named in the report, but their arrangements with the company after the deal were not described.
What to watch next
The CVR payments depend on milestones that have not been detailed in the report, so the final value paid to Unnatural Products holders may fall short of the $1.15 billion figure. The closing, targeted for the end of 2026, is subject to customary conditions.
Argenx shares closed at $927.21 on Friday, Nov. 6, up 3.63%, according to RTTNews.
Source: RTTNews



